Microsoft signs deal to sell AI-powered blood tests for CVD
Microsoft has signed a new deal with Prevencio, a cardiovascular health company based in Kirkland, Washington, to market and sell AI-powered cardiac blood tests to the public. The financial terms of the agreement were not made public.
Prevencio’s HART tests cover a variety of cardiovascular diseases, including obstructive coronary artery disease, heart attack, stroke, peripheral artery disease and more. The company says its tests have consistently been more accurate than other “standard risk scores or standard-of-care tests.”
“Microsoft’s efforts will complement our corporate focus on offering our HART tests to concierge physicians,” Rhonda Rhyne, Prevencio’s CEO, said in a prepared statement, adding that “robust physician and patient feedback” have played a key role in the development of the company’s solutions.
“With more than 15 million U.S. heart disease patients, and tens of millions of additional patients at risk, there is a clear unmet need for highly accurate, AI-based, multi-protein blood tests,” James L. Januzzi, MD, a cardiologist at Massachusetts General Hospital in Boston, said in the same statement. “Machine learning and AI, in conjunction with multiple proteins or genes, have been successful in improving diagnosis and care of cancer patients. It is rewarding to see these important technological advancements being applied to cardiac care.”
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.